Mazdutide Cost Breakdown: Brand, Compounded, Insurance & Savings Options

Introduction

Mazdutide pricing exists only in China today, where Innovent launched it under the brand name Xinerjia in mid-2025. The list price in China is roughly 800 to 1,200 Chinese yuan per monthly supply at the 6 mg maintenance dose, which works out to about $110 to $165 USD per month. That’s far below what comparable GLP-1 drugs cost in the United States.

In the US, the drug isn’t approved yet, and there’s no legal compounded option. The closest comparisons are list prices for Wegovy® (semaglutide) at $1,349 per month and Zepbound® (tirzepatide) at $1,059 per month. If Eli Lilly brings mazdutide to the US, pricing would likely be in the same general range as Zepbound, though competitive pressure could push it lower.

This article walks through what mazdutide costs where it’s currently available, what to expect in the US, current insurance coverage realities for the GLP-1 class, and what your realistic options are right now if you’re priced out of brand-name drugs.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

How Much Does Mazdutide Cost in China?

Mazdutide retails for roughly 800 to 1,200 yuan per month at the 6 mg maintenance dose, or about $110 to $165 USD. Innovent markets it under the brand name Xinerjia (信尔佳). Some sources report list prices closer to 700 yuan at the lower 4 mg dose.

Quick Answer: Mazdutide costs $110 to $165 USD per month in China at the maintenance dose

The Chinese launch pricing is dramatically lower than US GLP-1 prices, reflecting the differences in drug pricing systems. Chinese drug pricing involves national volume-based procurement and direct price negotiations between manufacturers and the NMPA. Eli Lilly’s tirzepatide is also sold in China at substantially lower prices than in the US.

For Chinese patients, mazdutide is covered by some regional insurance programs after the national approval in 2025. National Reimbursement Drug List (NRDL) inclusion is still being negotiated. Until that’s complete, patients largely pay out of pocket or through supplemental private insurance.

When Will Mazdutide Be Available in the US?

Mazdutide has no FDA approval and no announced filing date. Eli Lilly licensed global rights outside Greater China and is running phase 3 trials globally. The earliest realistic US availability is 2027 to 2028, depending on trial outcomes and FDA review timing.

Eli Lilly already sells tirzepatide (Mounjaro® and Zepbound) in the US, so they have an established commercial channel. Whether they push mazdutide to market in the US is a strategic question. Tirzepatide produces slightly more weight loss in trials, but mazdutide has the unique glucagon mechanism that could benefit specific populations (MASH patients, for example).

If Lilly does file, expect US list pricing in the $900 to $1,400 monthly range, similar to other branded GLP-1s. Insurance coverage would mirror what’s happening with Wegovy and Zepbound, meaning limited and inconsistent for weight loss but better for type 2 diabetes if the drug gets that indication.

What Does Wegovy and Zepbound Cost in the US for Comparison?

Wegovy (semaglutide for weight loss) lists at $1,349 per month. Zepbound (tirzepatide for weight loss) lists at $1,059. Both are subject to varying levels of insurance coverage and manufacturer savings programs.

Eli Lilly launched LillyDirect in 2024, selling Zepbound single-dose vials directly to cash-pay patients at $349 for the 2.5 mg starter, $499 for 5 mg, and $599 for 7.5 mg. This bypasses pharmacy benefit managers and offers significantly lower prices than the brand list. Novo Nordisk’s NovoCare offers similar cash pay pricing for Wegovy at $499 per month.

For diabetes indications (Ozempic® and Mounjaro), insurance coverage is much broader. Most commercial plans cover them with a copay structure. Out-of-pocket cost for insured patients ranges from $25 to $200 per month depending on plan tier and prior authorization status.

Is Compounded Mazdutide Available?

No. Compounded mazdutide is not legally available in the US. Compounding regulations under section 503A and 503B require that the active pharmaceutical ingredient be FDA-approved or on the FDA shortage list for that specific drug. Mazdutide is neither.

Compounding pharmacies that claim to offer mazdutide are operating outside the regulatory framework. The drug substance availability is also questionable, since no FDA-registered API manufacturer makes mazdutide for the US market.

If you see online ads or telehealth offers for compounded mazdutide, treat them with extreme skepticism. The legitimate path to mazdutide treatment is waiting for FDA approval, traveling to a country where it’s approved (like China), or participating in a clinical trial. Compounded semaglutide and tirzepatide remain legal options for patients during the FDA shortage period for those drugs.

What About Gray Market or International Sources?

Some patients consider importing mazdutide from China through online pharmacies. This is legally questionable and practically risky. The FDA generally permits personal importation of small quantities of medications for personal use under specific conditions, but enforcement varies.

The bigger risks are quality and authenticity. Counterfeit drugs are common in international pharmacy supply chains. Even legitimate Chinese mazdutide may not meet US handling and storage standards by the time it reaches you. Reconstitution, dosing accuracy, and sterility are all concerns.

Most US-based clinicians won’t manage a patient using imported drugs, leaving you without prescriber support for side effects or dose adjustments. This makes gray market sourcing a poor choice for most people, even setting aside the legal issues.

What Insurance Coverage Exists for GLP-1 Weight Loss Drugs?

Roughly 25% of US commercial insurance plans cover GLP-1 drugs for weight loss as of 2026, according to industry surveys. Medicare doesn’t cover them for weight loss (the Inflation Reduction Act language excludes obesity drugs). Medicaid coverage varies by state, with about 20 states offering some level of coverage.

For diabetes, coverage is the standard. About 95% of plans cover GLP-1s when prescribed for type 2 diabetes. The challenge for weight loss patients is the documentation: BMI above 30 (or 27 with comorbidities) is required, prior authorization is common, and step therapy may require trying other obesity drugs first.

Self-insured employer plans have flexibility to add or remove GLP-1 coverage. Many large employers (Walmart, Microsoft, Amazon) have specific GLP-1 programs for their employees. Smaller employers more often exclude this class to control premium costs.

Key Takeaway: Wegovy lists at $1,349 per month; Zepbound at $1,059 in the US for comparison

What Are the Cheapest Legitimate Options Today?

Compounded semaglutide and tirzepatide remain the most affordable legitimate options for many Americans during the FDA shortage period. Telehealth platforms like TrimRx offer monthly programs that include the medication, the prescriber consultation, and ongoing support, typically in the $150 to $300 per month range.

The free assessment quiz at TrimRx evaluates whether you’re a candidate for compounded semaglutide or tirzepatide and matches you to the right starting dose. This is the closest practical equivalent to mazdutide that’s available today, with extensive trial data backing both options.

Lilly Direct cash pay for Zepbound vials starts at $349 monthly for the 2.5 mg dose. Novo’s NovoCare for Wegovy vials starts at $499 monthly. Both require self-injection from a vial rather than a pen, which some patients find awkward but most adapt to within a couple of weeks.

How Much Does a Year of Mazdutide Treatment Cost?

In China, a year of mazdutide at maintenance dose costs roughly $1,300 to $2,000 USD out of pocket. That’s the total for 52 weeks of the medication, not including consultations or labs.

If mazdutide reaches the US at typical brand GLP-1 pricing, expect annual costs of $12,000 to $17,000 at list price, before any insurance coverage or manufacturer rebates. With a cash pay program similar to Zepbound’s, annual costs could drop to $4,000 to $7,000.

Insurance-covered patients with low copays might pay $300 to $2,400 annually, depending on plan structure. Patients in high-deductible plans typically pay the full negotiated rate (often $700 to $900 monthly) until they hit their deductible, then a percentage thereafter.

What Savings Programs Might Be Available?

Branded GLP-1 manufacturers all offer copay savings cards for insured patients. Wegovy’s savings program drops monthly cost to $0 to $25 for eligible patients with commercial insurance and coverage. Zepbound’s program offers similar discounts. These programs typically have annual benefit caps.

For uninsured cash-pay patients, manufacturer direct programs (LillyDirect, NovoCare) offer the steepest discounts, typically 40 to 60% off list price. These are vial-based programs rather than pen-based, which is the main tradeoff.

Patient assistance programs (PAPs) exist for some GLP-1s but eligibility is narrow, typically requiring household income under 250% of federal poverty level. Documentation requirements are substantial.

How Does Mazdutide Pricing Compare Globally?

Drug pricing varies dramatically by country. In China, mazdutide is at the low end of GLP-1 pricing globally. If it launches in Europe, expect prices similar to where semaglutide and tirzepatide land there: roughly €100 to €250 per month, often with full coverage through national health systems for qualifying patients.

The US is consistently the highest-priced market for GLP-1s. UK NHS covers tirzepatide and semaglutide with significant restrictions on who qualifies. Canada and Australia have public coverage with documentation requirements but lower out-of-pocket costs than the US.

Japan and South Korea are likely future markets for mazdutide. Both have GLP-1 markets with prices roughly 30 to 50% lower than US list prices.

Bottom line: Compounded semaglutide and tirzepatide remain accessible through telehealth and offer immediate options for budget-conscious patients

FAQ

Can I Import Mazdutide From China?

It’s not recommended. Personal importation is legally gray, drug quality from unofficial sources is unreliable, and US prescribers won’t support a treatment regimen with imported drugs.

Will Medicare Cover Mazdutide If It’s Approved?

Not for weight loss, under current law. Medicare Part D excludes obesity drugs. If mazdutide is approved for diabetes or cardiovascular indications, Medicare coverage would follow standard rules for those conditions.

Are There Mazdutide Patient Assistance Programs?

Not in the US, since the drug isn’t yet approved or marketed here. Innovent operates patient support in China, but those programs don’t cross borders.

How Much Does a Clinical Trial Enrollment Cost?

Clinical trials typically provide the study drug free of charge. Enrolling in a US mazdutide phase 3 trial through Lilly’s network is a way to access the drug at no medication cost. Trial participation has its own commitments (frequent visits, blood draws, study procedures).

What’s the Cheapest GLP-1 Option Overall?

Compounded semaglutide through telehealth is currently the cheapest legitimate option for most US patients. Monthly costs through programs like TrimRx are typically $150 to $300 including the medication.

Will Mazdutide Ever Be Available as a Generic?

Mazdutide is a peptide, not a small molecule. It can’t be generically copied the way oral pills can. Future “biosimilars” of mazdutide could lower prices but typically by only 15 to 30%, not 70 to 80% like small molecule generics.

Does Insurance Coverage for Mazdutide Require BMI Documentation?

Coverage isn’t an active question yet because the drug isn’t FDA approved. If it becomes available for obesity, expect typical GLP-1 documentation requirements: BMI thresholds, comorbidity confirmation, and possibly prior weight loss attempts.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.